Premium
Serum β 2 microglobulin in malignant lymphoproliferative disorders
Author(s) -
Constantinides Ioannis P.,
Pathouli Christina,
Karvountzis Gerasimos,
Papadopoulos Perikles,
VarvoutsiConstantinides Maria,
Eliakis Polivios,
Hadziyannis Stephanos,
Komninos Zacharias
Publication year - 1985
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19850515)55:10<2384::aid-cncr2820551014>3.0.co;2-3
Subject(s) - medicine , beta 2 microglobulin , lymphoproliferative disorders , pathology , immunology , oncology , lymphoma
Serum beta‐2‐microglobulin (S‐β 2 M) was measured at diagnosis in 44 patients with lymphocytic leukemias and 47 with malignant lymphomas. Among patients with chronic lymphocytic leukemia (CLL) S‐β 2 M was raised (>3 mg/1) in 74% and in 23.5% of those with acute lymphoblastic leukemia (ALL). The frequencies for non‐Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) were 59.2% and 40%, respectively. In CLL patients high serum values correlated with large tumor mass, as estimated by Rai's clinical criteria ( P < 0.001), by total peripheral lymphocytes (r = 0.41, P < 0.05) and by the percentage of bone marrow infiltration of the lymphocytes ( P < 0.01). A significant relation was also found in CLL patients between S‐β 2 M level and survival ( P < 0.05). In ALL no association was found between S‐β 2 M level with peripheral lymphoblast concentration, French‐American‐British (FAB) subclassification, splenomegaly, and survival. In NHL patients a significant association was found between S‐β 2 M levels and stage of disease ( P < 0.01) and an obscure relation ( P < 0.01) and an obscure relation ( P < 0.1) with the presence of lymph nodes greater than 3 cm in diameter, splenomegaly, and hepatomegaly. No significant association was found between S‐β 2 M level and histologic subtypes, presence of B symptoms, bone marrow involvement, and survival. In HD patients a significant association was found between the level of S‐β 2 M and stage of disease ( P < 0.05) and presence of splenomegaly ( P < 0.05). No association was found between S‐β 2 M level and histologic subtypes, lymph nodes greater than 3 cm in diameter, bone marrow involvement, and B symptoms. A significant relation was found between S‐β 2 M level and survival in HD patients with widespread disease ( P < .025).